Form 4: Pacira SVP Sells Shares, Covers Taxes

Pacira BioSciences' Senior VP of Finance, Lauren Riker, reported the sale of 4,000 shares under a 10b5-1 plan and the withholding of 2,751 shares for tax obligations.

Summary

• Lauren Riker, Senior Vice President, Finance of Pacira BioSciences, Inc., reported changes in her beneficial ownership.
• On January 30, 2026, 2,751 shares of common stock were withheld by the issuer at a price of $20.54 per share to cover tax withholding obligations related to a restricted stock unit award vesting.
• On February 2, 2026, 4,000 shares of common stock were sold at a weighted average price of $20.81 per share, with individual transaction prices ranging from $20.35 to $21.28.
• These sales were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Lauren Riker beneficially owns 52,313.242 shares of Pacira BioSciences, Inc. common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. Insider sales under a 10b5-1 plan are pre-scheduled and tax-related dispositions are routine, neither indicating significant positive nor negative company-specific news.

Positives

• The sale of shares was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an immediate reaction to new information.

Negatives

• A Senior Vice President of Finance sold 4,000 shares of common stock.
• Additional shares were withheld to cover tax obligations, reducing direct ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures of insider transactions and do not typically provide insights into broader industry trends or competitive positioning. These transactions reflect individual compensation and financial planning rather than strategic corporate moves.

Stakeholder Impact

• Shareholders: Minor dilution from the sale of shares, but the overall impact is negligible given the small number of shares relative to the company's total outstanding shares. The 10b5-1 plan indicates a pre-planned sale, reducing concerns about insider sentiment.

Key Dates

Recommendation

The reported transactions are routine insider activities, specifically a pre-planned sale under a 10b5-1 plan and tax-related share withholding. These events do not provide new fundamental information about Pacira BioSciences, Inc. that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as existing investment decisions should be based on broader company fundamentals rather than these standard insider disclosures.

Keywords

Pacira BioSciences, PCRX, Form 4, Insider Trading, Stock Sale, Lauren Riker, 10b5-1 Plan, Restricted Stock Units, Tax Withholding